Author: Chang Chen; Jianying Huang; Zhenshun Cheng; Jianyuan Wu; Song Chen; Yongxi Zhang; Bo Chen; Mengxin Lu; Yongwen Luo; Jingyi Zhang; Ping Yin; Xinghuan Wang
Title: Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial Document date: 2020_3_20
ID: 14he8n3u_29
Snippet: The copyright holder for this preprint (which was not peer-reviewed) is the . https://doi.org/10.1101/2020.03.17.20037432 doi: medRxiv preprint Table 3 patients in the Favipiravir group and 14/120 (11.67%) patients in the Arbidol group (P=0.0174). Hence, we conclude that for secondary outcomes, Favipiravir significantly shortened the latency to relief for cough and pyrexia. Favipiravir was not associated with a decreased rate for AOT or NMV, dysp.....
Document: The copyright holder for this preprint (which was not peer-reviewed) is the . https://doi.org/10.1101/2020.03.17.20037432 doi: medRxiv preprint Table 3 patients in the Favipiravir group and 14/120 (11.67%) patients in the Arbidol group (P=0.0174). Hence, we conclude that for secondary outcomes, Favipiravir significantly shortened the latency to relief for cough and pyrexia. Favipiravir was not associated with a decreased rate for AOT or NMV, dyspnea, overall respiratory failure rate, ICU admission or all-cause mortality. All rights reserved. No reuse allowed without permission. author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
Search related documents:
Co phrase search for related documents- Arbidol group and pyrexia cough: 1, 2, 3, 4
- Arbidol group and pyrexia cough relief: 1, 2
- cause mortality and decreased rate: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
- cause mortality and failure rate: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
- cause mortality and ICU admission: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73
- cause mortality and pyrexia cough: 1
- cause mortality and pyrexia cough relief: 1
- cause mortality and respiratory failure rate: 1, 2, 3, 4
- cause mortality and secondary outcome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73
- cause mortality ICU admission and ICU admission: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36
- cause mortality ICU admission and secondary outcome: 1, 2
- decreased rate and failure rate: 1, 2, 3, 4, 5, 6, 7
- decreased rate and ICU admission: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
- decreased rate and secondary outcome: 1, 2, 3, 4, 5, 6, 7, 8, 9
- failure rate and ICU admission: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16
- failure rate and pyrexia cough: 1
- failure rate and pyrexia cough relief: 1
- failure rate and respiratory failure rate: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73
- failure rate and secondary outcome: 1, 2, 3, 4, 5, 6, 7, 8
Co phrase search for related documents, hyperlinks ordered by date